期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 111, 期 2, 页码 335-344出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2021.09.006
关键词
N-terminal pyroglutamate; monoclonal antibodies; IgG-like bispecific antibodies; lyophilization ion exchange chromatography; hydrophobic interaction chromatography; peptide mapping
资金
- AstraZeneca
In this study, N-terminal E cyclization was identified as the major degradation pathway for monoclonal antibodies and bispecific antibodies in lyophilized formulations. The use of salt-gradient ion exchange chromatography and hydrophobic interaction chromatography effectively separated pE, and pE did not affect the binding activity of the antibodies. In vitro experiments suggested a potential role of serum matrix in pE conversion.
N-terminal glutamate (E) cyclization to form pyroglutamate (pE) generates charge heterogeneities for mAbs and proteins. Thus far, pE formation rate in lyophilized formulation as compared to in liquid formulation has not been reported. Impact of pE on antibody biological activity has only been predicted or assessed using stressed samples that may contain other confounding degradations besides pE. Additionally, application of hydrophobic interaction chromatography (HIC) to separate pE has not been reported. In our study, N-terminal E cyclization was identified as the major degradation pathway in lyophilized formulation at elevated temperature for both monoclonal antibody (mAb-A) and IgG-like bispecific antibody (bsAb-A). pE was enriched in salt-gradient ion exchange chromatography (IEC) as pre-peak and in HIC as post-peak for both mAb-A and bsAb-A. Structure-function studies with pE-enriched IEC and HIC fractions confirmed that pE did not affect binding activities for mAb-A and bsAb-A. In vitro incubation of bsAb-A in serum and PBS revealed that the serum matrix may play a role in pE conversion in human serum, in contrast to the chemical reaction mechanism reported. These techniques can help in characterization of N-terminal E-to-pE cyclization and quality attribute severity assessment during therapeutic protein product development. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据